52 / 156
864
28. Lawlor PG, Bush SH. Delirium in patients with cancer: assessment,
impact, mechanisms and management Nat. Rev. Nat Rev Clin
Oncol. 2015 Feb;12(2):77-92
29. Inouye SK, Charpentier PA. Precipitating factors for delirium
in hospitalized elderly persons. Predictive model and
interrelationship with baseline vulnerability. JAMA. 1996 Mar
20;275(11):852-7.
30. Maldonado JR, Neuropathogenesis of delirium: review of current
etiologic theories and common pathways. Am J Geriatr Psychiatry.
2013 Dec;21(12):1190-222.
31. De Rooij SE, van Munster BC, Korevaar JC, Levi M. Cytokines and
acute phase response in delirium. J. Psychosom. Res. 2007, 62,
521–525.
32. Poon DC, Ho YS, Chiu K, Chang RC. Cytokines: how important
are they in mediating sickness? Neurosci Biobehav Rev. 2013
Jan;37(1):1-10.
33. Van Gool WA, van de Beek D, Eikelenboom P.. Systemic infection
and delirium: when cytokines and acetylcholine collide. Lancet.
2010 Feb 27;375(9716):773-5.
34. Casarett DJ, Inouye SK, American College of Physicians-American
Society of Internal Medicine End-of-Life Care Consensus Panel.
Diagnosis and management of delirium near the end of life.. Ann
Intern Med. 2001 Jul 3;135(1):32-40
35. Trzepacz PT, Breitbart W, Franklin J, Levenson J, Martini D, Wang
P. Practice guideline for the treatment of patients with delirium:
American Psychiatric Association.AmJ Psychiatry 2010 156:1–20, 199
36. Brajtman S, Wright D, Hogan DB, Allard P, Bruto V, Burne D, Gage
L, Gagnon PR, Sadowski CA, Helsdingen S, Wilson K. Developing
guidelines on the assessment and treatment of delirium in older
adults at the end of life. Can Geriatr J. 2011 Jun;14(2):40–50
37. European Delirium Association: www.europeandeliriumassociation.
com visita 2017
38. NICE Guidelines CG103 Delirium: diagnosis, prevention
andmanagement. 2010.
39. O’Mahony R, Murthy L, Akunne A, Young J. Guideline development
group. Synopsis of the national institute for health and clinical
excellence guideline for prevention of delirium. Ann Intern Med.
2011 Jun 7;154(11):746-51.
40. Bush SH, Bruera E, Lawlor PG, Kanji S, Davis DH, Agar M, et al.
Clinical practice guidelines for delirium management: potential
application in palliative care. J Pain Symptom Manage. 2014
Aug;48(2):249-58.
41. Hshieh T, Yue J, Oh E, Puelle M, Dowal S,Travison T, Inouye S.
Effectiveness of multi-component non-pharmacologic delirium
interventions: A Meta-analysis. JAMA Intern Med. 2015
Apr;175(4):512-20.
42. Caplan GA, Harper EL. Recruitment of volunteers to improve
vitality in the elderly: the REVIVE study. Intern Med J. 2007
Feb;37(2):95-100.
43. Rubin FH, Neal K, Fenlon K, Hassan S, Inouye SK. Sustainability
and scalability of the hospital elder life program at a community
hospital. J Am Geriatr Soc. 2011 Feb;59(2):359-65
44. Inouye SK, Bogardus ST Jr, Charpentier PA, Leo-Summers L,
Acampora D, Holford TR, et al. A multicomponent intervention
to prevent delirium in hospitalized older patients. N Engl J Med.
1999 Mar 4;340(9):669-76.
45. Gagnon P, Allard P, Gagnon, B, Merette C, Tardif, F. Delirium
prevention in terminal cancer: assessment of a multicomponent
intervention. Psychooncology. 2012 Feb;21(2):187-94
46. Chen S, Shi L, Liang F, Xu L, Desislava D, Wu Q, Zhang J. Exogenous
Melatonin for DeliriumPrevention: aMeta-analysis of Randomized
Controlled Trials. Mol Neurobiol. 2016 Aug;53(6):4046-4053
47. Lawlor PG, Gagnon B, Mancini IL, Pereira JL, Hanson J, Suarez-
Almazor ME, et al. Occurrence, causes, and outcome of delirium
in patients with advanced cancer: a prospective study. Arch Intern
Med. 2000 Mar 27;160(6):786-94.
48. Gaudreau, JD, Gagnon P, Harel F, Roy MA, TremblayA. Psychoactive
medications and risk of delirium in hospitalized cancer patients. J
Clin Oncol. 2005 Sep 20;23(27):6712-8.
49. Morita T, Tei Y, Tsunoda J, Inoue S, Chihara, S. Underlying
pathologies and their associations with clinical features in
terminal delirium of cancer patients. J Pain Symptom Manage.
2001 Dec;22(6):997-1006.
50. Hu MI, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Misiorowski
W. Denosumab for patients with persistent or relapsed
hypercalcemia of malignancy despite recent bisphosphonate
treatment. J Natl Cancer Inst. 2013 Sep 18;105(18):1417-20.
51. Kacprowicz, R. F. & Lloyd, J. D. Electrolyte complications ofmalignancy.
Hematol Oncol Clin North Am. 2010 Jun;24(3):553-65.
52. Quraishi SA, Litonjua AA, Elias KM, Gibbons FK, Giovannucci E,
Camargo CA Jr, et al. Association between pre-hospital vitamin D
status and hospital-acquired new-onset delirium. Br J Nutr. 2015
Jun 14;113(11):1753-60.
53. El-Kaissi S, Kotowicz MA, Berk M, Wall JR. Acute delirium in the
setting of primary hypothyroidism: the role of thyroid hormone
replacement therapy. Thyroid. 2005 Sep;15(9):1099-101.
54. Osiezagha K, Ali S, Freeman C, Barker NC, Jabeen S, Maitra S,
Olagbemiro Y, Richie W, Bailey RK. Thiamine deficiency and
delirium. Innov Clin Neurosci. 2013 Apr;10(4):26-32.
55. Gofton TE, Graber J, Carver, A. Identifying the palliative care
needs of patients living with cerebral tumors and metastases: a
retrospective analysis. J Neurooncol. 2012 Jul;108(3):527-34
56. Yamanaka R1, Koga H, Yamamoto Y, Yamada S, Sano T, Fukushige
T. Characteristics of patients with brain metastases from lung
cancer in a palliative care center. Support Care Cancer. 2011
Apr;19(4):467-73.
57. Damek DM. Cerebral edema, altered mental status, seizures, acute
stroke, leptomeningeal metastases, and paraneoplastic syndrome.
Hematol Oncol Clin North Am. 2010 Jun;24(3):515-35.
58. Sarin R, Murthy V. Medical decompressive therapy for primary
and metastatic intracranial tumours. Lancet Neurol. 2003
Jun;2(6):357-65.
59. Matsuoka H, Yoshiuchi K, Koyama A, Otsuka M, Nakagawa K.
Chemotherapeutic drugs that penetrate the blood-brain barrier
affect the development of hyperactive delirium in cancer patients.
Palliat Support Care. 2015 Aug;13(4):859-64.
60. Hinchey J, Chavez C, Appignani B, Breen J, Pao L, Wang A, et al. A
reversible posterior leukoencephalopathy syndrome. N Engl J Med.
1996 Feb 22;334(8):494-500.
61. Lou E, Turner S, Sumrall A, Reardon DA, Desjardins A,
Peters KB, et al. Bevacizumab-induced reversible posterior
leukoencephalopathy syndrome and successful retreatment in a
patient with glioblastoma. J. Clin. Oncol. 2011. 29, e739–e742.
62. Sclafani, F, Giuseppe G, Mezynksi, J, Collins C, Crown, J Reversible
posterior leukoencephalopathy syndrome and bevacizumab in
breast cancer. J. Clin. Oncol. 2012. 30, e257–e259.
63. Maeda T, Kikuchi E, Matsumoto K, Yazawa S, Hagiuda J, Miyajima
A, et al. Gemcitabine and cisplatin chemotherapy induced
[REV. MED. CLIN. CONDES - 2017; 28(6) 855-865]